Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.58 |
| ▸ | PTGFR | P43088 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491515 | 0.90 | FFAR1 (0.72) | FFAR1FFAR4PTGFRLMNACNR1 | |
| SCHEMBL12500258 | 0.87 | FFAR1 (0.50) | FFAR1FFAR4PTGFRFOLH1HTR2B | |
| SCHEMBL19062339 | 0.86 | FFAR1 (0.49) | FFAR1FFAR4PTGFRFOLH1HTR2B | |
| SCHEMBL25342051 | 0.82 | HDAC3 (0.76) | FFAR1HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL28248372 | 0.82 | HTR2B (0.54) | FFAR1FFAR4FOLH1HTR2BCNR1 | |
| SCHEMBL28865565 | 0.82 | HTR2B (0.50) | FFAR1FFAR4FOLH1HTR2BCNR1 | |
| SCHEMBL27718564 | 0.82 | GLA (0.49) | FFAR1FFAR4FOLH1HTR2BLMNA | |
| SCHEMBL1246091 | 0.82 | FFAR1 (0.59) | FFAR1FFAR4SMN1; SMN2PTGFRFOLH1 | |
| SCHEMBL7335965 | 0.81 | FFAR1 (0.57) | FFAR1FFAR4FOLH1HTR2BLMNA | |
| SCHEMBL6962952 | 0.81 | DRD2 (0.49) | FFAR1FFAR4FOLH1HTR2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3769776-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-2822572-B1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-109415330-A | Novel difluoro keto acyl amine derivative as HTRA1 inhibitor | 豪夫迈·罗氏有限公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-3432904-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| WO-2018165575-A2 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-09-13 | — | — | WO | disclosed |
| EP-3347372-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | Aileron Therapeutics, Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3294318-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2017165299-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| EP-3197477-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | Aileron Therapeutics, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197478-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2013123266-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013059525-A1 | PEPTIDOMIMETIC MACROCYLES | AILERON THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20130065259-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | CITY OF HOPE (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2012173846-A2 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-5591769-A | PYRROLIDINE DERIVATIVES; ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541343-A | ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| CN-1004351-B | Method for preparing selaginellin related compound with phenylene | 微生物化学研究会 | 1989-05-31 | — | — | CN | disclosed |
| CN-85101425-A | Have Si Baige Eyring allied compound of phenylene and preparation method thereof | — | 1987-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | FFAR1 55/4885FFAR4 125/4885HDAC3 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.